Clinical Oncology – Hospital Komárno

Penoxal was administered to 15 patients who were using the product while on chemotherapy/RAT-CHT resp./ for 2-3 months in a dose of 50 mg 4cps daily as a complementary therapy.

4 pts with gynaecological malignancies

2 pts with breast cancer

3 pts with lung cancer

6 pts with GIT cancer / of those lx pancreatic, lx oesophageal

Patients tolerated the product very well; no side effects were noted in association with its use. It may be suggested that patients tolerated the chemotherapy better and were able to receive the planned cycles without any delays or discontinuations. We noticed that most of them have objectively improved their overall condition.

Deterioration was noted in a patient with pancreatic cancer and in a patient with a progressing ovarian serous adenocarcinoma as those were high-risk and aggressive diseases and primarily metastatic.

Penoxal administration in combination with the recommended cancer treatment may be regarded as a significantly supportive way to cancer treatments. The patient group using the product was heterogeneous and relatively small. The testing period was relatively short. However, outcomes seem very promising with some good prospects.

Penoxal was administered to 15 patients who were using it while on chemotherapy / RAT-CHT resp. / for 2-3 months in a dose of 50 mg 4 cps daily as a complementary therapy.

Mudr. Rosinská Olga
Clinical Oncology
Forlife General Hospital Komárno

27/7/2016